Related Experiment Video
Updated: Jun 8, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Horizon scanning for novel therapeutics for the treatment of prostate cancer
Diletta Bianchini1, Andrea Zivi, Shahneen Sandhu
1The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK.
Importance Of The Field:
Treatment options for patients with advanced prostate cancer (PCa) remain limited. Improved understanding of the underlying molecular drivers of prostate cancer pathogenesis, progression and resistance development has provided the fundamental basis for rational targeted drug design.
Areas Covered In This Review:
This review will discuss the most recent developments in the field of prostate cancer therapies including key findings such as the identification of ETS gene rearrangements, the dissection of prostate cancer molecular heterogeneity and the discovery that castration-resistant prostate cancer (CRPC) remains androgen-driven despite the androgen-depleted milieu, thus making androgen receptor signaling a continued focus of molecularly targeted treatments. A multitude of new molecularly targeted agents are in clinical development and are highly likely to change the current treatment paradigm.
What The Reader Will Gain:
This review will outline the current clinical development of molecular targeted treatments in CRPC.
Take Home Message:
Unraveling the complex molecular biology that underpins this heterogeneous disease may pave the way to personalized therapy with a wide range of rationally targeted agents and combination treatments. In conclusion, we can predict that the rational clinical development of new targeted drugs will improve the outcome of men with prostate cancer in the years ahead.
Insights
New targeted drugs offer hope for advanced prostate cancer (PCa). Understanding molecular drivers and androgen receptor signaling in castration-resistant prostate cancer (CRPC) is key to developing personalized treatments.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Advanced prostate cancer (PCa) treatment options are limited.
- Molecular understanding of PCa pathogenesis, progression, and resistance drives targeted drug design.
Purpose of the Study:
- To review recent advancements in prostate cancer therapies.
- To highlight the development of molecularly targeted agents for advanced PCa.
Main Methods:
- Review of key findings in prostate cancer research.
- Analysis of molecular heterogeneity and androgen receptor signaling in CRPC.
- Assessment of ongoing clinical development of targeted agents.
Main Results:
- Identification of ETS gene rearrangements in PCa.
- Understanding CRPC as androgen-driven despite castration.
- Numerous targeted agents are in clinical development.
Conclusions:
- Personalized therapy for heterogeneous PCa through molecular understanding.
- Targeted agents and combination treatments show promise.
- New targeted drugs are expected to improve outcomes for men with prostate cancer.
More Related Videos
08:05Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
